Funding and Investments

Oct 01, 2011
BioPharm International
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
Sep 20, 2011
BioPharm International
By BioPharm International Editors
The UK?s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.
Jul 01, 2011
BioPharm International
Strong pipelines, approvals, and deals drive up market cap.
May 10, 2011
BioPharm International
On Apr. 29, 2011, a federal appeals court has lifted a ban on federal funding for embryonic stem cell (ESC) research. The move was celebrated by researchers hoping to use such cells for research, but it is likely that the decision will be appealed. Embryonic stem cells are pluripotent cells derived from embryonic tissue in a process that usually results in the destruction of the embryo. The ban on funding did not apply to stem cells derived from adult tissue.
Apr 01, 2011
BioPharm International
Industry starts the year with a positive spin.
Feb 22, 2011
BioPharm International
President's Budget Allocates More Funding to FDA
Jan 01, 2011
BioPharm International
Business models that were used to create current value are no longer going to be effective going forward.
Oct 01, 2010
BioPharm International
Biotech's mid-sized elites position themselves for growth.
Jul 01, 2010
BioPharm International
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
Apr 01, 2010
BioPharm International
As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
native1_300x100
lorem ipsum